扩大 GMP 级多巴胺能细胞治疗帕金森病的规模

IF 19.8 1区医学 Q1 CELL & TISSUE ENGINEERING Cell stem cell Pub Date : 2024-01-04 DOI:10.1016/j.stem.2023.12.005

Thomas Foltynie

{"title":"扩大 GMP 级多巴胺能细胞治疗帕金森病的规模","authors":"Thomas Foltynie","doi":"10.1016/j.stem.2023.12.005","DOIUrl":null,"url":null,"abstract":"<p>Stem cell therapy for Parkinson’s disease requires demonstration of safety and efficacy of dopaminergic cells derived from a cell line, consideration of dose, and whether this is deliverable at scale. Park et al. demonstrate these requirements for a new hESC line and that their manufacturing methods allow for its scalability.</p>","PeriodicalId":9665,"journal":{"name":"Cell stem cell","volume":"8 1","pages":""},"PeriodicalIF":19.8000,"publicationDate":"2024-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Scaling up GMP-grade dopaminergic cells for Parkinson’s disease\",\"authors\":\"Thomas Foltynie\",\"doi\":\"10.1016/j.stem.2023.12.005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Stem cell therapy for Parkinson’s disease requires demonstration of safety and efficacy of dopaminergic cells derived from a cell line, consideration of dose, and whether this is deliverable at scale. Park et al. demonstrate these requirements for a new hESC line and that their manufacturing methods allow for its scalability.</p>\",\"PeriodicalId\":9665,\"journal\":{\"name\":\"Cell stem cell\",\"volume\":\"8 1\",\"pages\":\"\"},\"PeriodicalIF\":19.8000,\"publicationDate\":\"2024-01-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cell stem cell\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.stem.2023.12.005\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CELL & TISSUE ENGINEERING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell stem cell","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.stem.2023.12.005","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL & TISSUE ENGINEERING","Score":null,"Total":0}

引用次数: 0

摘要

治疗帕金森病的干细胞疗法需要证明从细胞系中提取的多巴胺能细胞的安全性和有效性、考虑剂量以及是否可以规模化生产。Park 等人的研究证明了新的 hESC 细胞系的这些要求，并证明了他们的制造方法使其具有可扩展性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Scaling up GMP-grade dopaminergic cells for Parkinson’s disease

Stem cell therapy for Parkinson’s disease requires demonstration of safety and efficacy of dopaminergic cells derived from a cell line, consideration of dose, and whether this is deliverable at scale. Park et al. demonstrate these requirements for a new hESC line and that their manufacturing methods allow for its scalability.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cell stem cell 生物-细胞生物学

CiteScore

37.10

自引率

2.50%

发文量

151

审稿时长

42 days

期刊介绍： Cell Stem Cell is a comprehensive journal covering the entire spectrum of stem cell biology. It encompasses various topics, including embryonic stem cells, pluripotency, germline stem cells, tissue-specific stem cells, differentiation, epigenetics, genomics, cancer stem cells, stem cell niches, disease models, nuclear transfer technology, bioengineering, drug discovery, in vivo imaging, therapeutic applications, regenerative medicine, clinical insights, research policies, ethical considerations, and technical innovations. The journal welcomes studies from any model system providing insights into stem cell biology, with a focus on human stem cells. It publishes research reports of significant importance, along with review and analysis articles covering diverse aspects of stem cell research.